Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
NCT07581145 on ClinicalTrials.gov · last registry update 2026-05-12
A small phase 3 — 52 participants, against a typical 424. Due to report December 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Proportion of clinical healed index foot ulcer at week 20. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Ole Lander Svendsen
- Sponsor type
- Other
- Enrollment
- 52
- Started
- 2026-04-24
- Primary completion
- 2028-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proportion of clinical healed index foot ulcer at week 20
Conditions studied
Foot Ulcer Due to Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.